Effectiveness of an 8-Week Primaquine Regimen for Plasmodium vivax Malaria
Author Information
Author(s): Leslie Toby, Mayan Ismail, Mohammed Nasir, Erasmus Panna, Kolaczinski Jan, Whitty Christopher J. M., Rowland Mark
Primary Institution: London School of Hygiene and Tropical Medicine
Hypothesis
Is an 8-week, once weekly primaquine regimen effective at preventing relapse of Plasmodium vivax malaria without the need for G6PD testing?
Conclusion
The 8-week primaquine regimen is more effective at preventing relapse of vivax malaria than the current standard treatment with chloroquine alone.
Supporting Evidence
- There were 22 treatment failures in the placebo group compared to only 1 in the 14-day PQ group and 4 in the 8-week PQ group.
- The 8-week PQ regimen showed a significantly lower failure rate compared to placebo.
- Only one G6PD deficient patient was identified during the trial, and no serious adverse events were reported.
Takeaway
This study shows that taking a special medicine called primaquine once a week for 8 weeks can help stop people from getting sick again from a type of malaria called vivax.
Methodology
200 patients with confirmed Plasmodium vivax were randomly assigned to receive either an 8-week primaquine regimen, a placebo, or a 14-day primaquine regimen, all alongside standard chloroquine treatment.
Limitations
The study was not powered to show equivalence between the 14-day and 8-week PQ arms.
Participant Demographics
Patients were primarily Afghan refugees aged 3 years and older, with a median age of 10 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%CI: 0.01-0.2
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website